Price movement over the last 24 hours
Agilent Technologies Inc vs Nano Dimension Ltd - ADR — how do they compare? Agilent Technologies Inc trades at $128.5 (market cap $37.04B), while Nano Dimension Ltd - ADR trades at $1.51 (market cap $307.34M). The key difference: Agilent Technologies Inc is far larger — about 120.5× Nano Dimension Ltd - ADR's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals.
| A | NNDM | |
|---|---|---|
Market Cap | $37.04B | $307.34M |
Sector | Health | Technology |
52-Week High | $157.20 | $2.14 |
52-Week Low | $110.24 | $1.21 |
Enterprise Value | $38.59B | -$102.00M |
Dividend Yield | 0.78% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Nano Dimension (NNDM) trades at $1.46, up 0.69% on the day, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $102.44M but a net loss of $293.30M, with negative cash flow from operations of $101.28M. Recent news highlights a proposed business combination with Infinite Epigenetics and ongoing shareholder disputes with Murchinson Ltd., reflecting strategic shifts and internal tensions.
Outlook remains challenged by persistent losses and cash burn, though the low P/B of 0.63 may attract value investors. Key risks include execution of the strategic plan, shareholder approval of the Infinite Epigenetics deal, and achieving profitability. Opportunities lie in cost reductions and potential synergies from mergers, but the stock faces significant fundamental headwinds.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →